Citations (98)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Juliana Tournebize, Valérie Gibaja & Jean-Pierre Kahn. (2017) Acute effects of synthetic cannabinoids: Update 2015. Substance Abuse 38:3, pages 344-366.
Read now
Read now
Robert J. Tait, David Caldicott, David Mountain, Simon L. Hill & Simon Lenton. (2016) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clinical Toxicology 54:1, pages 1-13.
Read now
Read now
Y. Finkelstein, J. R. Hutson, S. B. Freedman, P. Wax & J. Brent. (2013) Drug-induced seizures in children and adolescents presenting for emergency care: Current and emerging trends. Clinical Toxicology 51:8, pages 761-766.
Read now
Read now
Anders Helander, Olof Beck, Robert Hägerkvist & Peter Hultén. (2013) Identification of novel psychoactive drug use in Sweden based on laboratory analysis – initial experiences from the STRIDA project. Scandinavian Journal of Clinical and Laboratory Investigation 73:5, pages 400-406.
Read now
Read now
Articles from other publishers (94)
Giorgia Corli, Micaela Tirri, Sabrine Bilel, Arianna Giorgetti, Tatiana Bernardi, Federica Boccuto, Martina Borsari, Raffaele Giorgetti & Matteo Marti. (2023) Ethanol enhances JWH-018-induced impairment of sensorimotor and memory functions in mice: From preclinical evidence to forensic implication in Driving Under the Influence of Drugs. Drug and Alcohol Dependence 247, pages 109888.
Crossref
Crossref
Alev Er & Sefa Çelik. 2023. Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases. Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases
235
257
.
Patrick Dahm, Andreas Thomas, Markus A. Rothschild, Mario Thevis & Katja Mercer-Chalmers-Bender. (2021) Phase I-metabolism studies of the synthetic cannabinoids PX-1 and PX-2 using three different in vitro models. Forensic Toxicology 40:2, pages 244-262.
Crossref
Crossref
Martin F. Casey & Alex F. Manini. 2022. Novel Psychoactive Substances. Novel Psychoactive Substances
415
446
.
Neelambika Revadigar, Ching Tary Yu & Isabelle Silverstone-Simard. 2022. Substance and Non-Substance Related Addictions. Substance and Non-Substance Related Addictions
185
194
.
Michal Ordak, Aleksandra Zmysłowska, Miłosz Bielski, Daniel Rybak, Maja Tomaszewska, Katarzyna Wyszomierska, Aleksandra Kmiec, Natalia Garlicka, Maria Zalewska, Michal Zalewski, Tadeusz Nasierowski, Elzbieta Muszynska & Magdalena Bujalska-Zadrozny. (2021) Pharmacotherapy of Patients Taking New Psychoactive Substances: A Systematic Review and Analysis of Case Reports. Frontiers in Psychiatry 12.
Crossref
Crossref
Yigit Sezer, Ayse Tarbin Jannuzzi, Marilyn A Huestis & Buket Alpertunga. (2020)
In vitro
assessment of the cytotoxic, genotoxic and oxidative stress effects of the synthetic cannabinoid JWH-018 in human SH-SY5Y neuronal cells
. Toxicology Research 9:6, pages 734-740.
Crossref
Crossref
Masahiko Funada, Mika Takebayashi-Ohsawa & Ken-ich Tomiyama. (2020) Synthetic cannabinoids enhanced ethanol-induced motor impairments through reduction of central glutamate neurotransmission. Toxicology and Applied Pharmacology 408, pages 115283.
Crossref
Crossref
Laura Orsolini, Stefania Chiappini, Duccio Papanti, Domenico De Berardis, John M. Corkery & Fabrizio Schifano. (2019) The Bridge Between Classical and “Synthetic”/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective. Frontiers in Psychiatry 10.
Crossref
Crossref
Eef L. TheunissenNadia R.P.W. HuttenNatasha L. MasonStefan W. ToennesKim P.C. KuypersJohannes G. Ramaekers. (2019) Neurocognition and Subjective Experience Following Acute Doses of the Synthetic Cannabinoid JWH-018: Responders Versus Nonresponders. Cannabis and Cannabinoid Research 4:1, pages 51-61.
Crossref
Crossref
Ahmet Kırgız & Havva Kaldırım. (2017) Bilateral multiple exudative retinal detachments and macular edema in a patient diagnosed with synthetic cannabinoid (Bonzai) intoxication. International Ophthalmology 39:1, pages 237-241.
Crossref
Crossref
Eef L Theunissen, Nadia R P W Hutten, Natasha L Mason, Stefan W Toennes, Kim P C Kuypers, Eliza B de Sousa Fernandes Perna & Johannes G Ramaekers. (2018) Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH-018: a phase 1, placebo-controlled, pilot study. British Journal of Pharmacology 175:1, pages 18-28.
Crossref
Crossref
Lenka Hruba & Lance R. McMahon. (2017) Apparent Affinity Estimates and Reversal of the Effects of Synthetic Cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by Rimonabant in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics 362:2, pages 278-286.
Crossref
Crossref
Noreen D Mdege, Nick Meader, Charlie Lloyd, Steve Parrott & Jim McCambridge. (2017) The Novel Psychoactive Substances in the UK Project: empirical and conceptual review work to produce research recommendations. Public Health Research 5:4, pages 1-138.
Crossref
Crossref
Marie Claire Van Hout & Evelyn Hearne. (2016) User Experiences of Development of Dependence on the Synthetic Cannabinoids, 5f-AKB48 and 5F-PB-22, and Subsequent Withdrawal Syndromes. International Journal of Mental Health and Addiction 15:3, pages 565-579.
Crossref
Crossref
Shanna Marrinan, Andres Roman-Urrestarazu, Declan Naughton, Emerlinda Levari, John Collins, Robert Chilcott, Giuseppe Bersani & Ornella Corazza. (2017) Hair analysis for the detection of drug use-is there potential for evasion?. Human Psychopharmacology: Clinical and Experimental 32:3, pages e2587.
Crossref
Crossref
Neil A. Patel, Jason M. Jerry, Xavier F. Jimenez & Stephen T. Hantus. (2017) New-Onset Refractory Status Epilepticus Associated With the Use of Synthetic Cannabinoids. Psychosomatics 58:2, pages 180-186.
Crossref
Crossref
Mark Henry Alon & Margaret Olibrice Saint-Fleur. (2017) Synthetic cannabinoid induced acute respiratory depression: Case series and literature review. Respiratory Medicine Case Reports 22, pages 137-141.
Crossref
Crossref
Colin Davidson, Jolanta Opacka-Juffry, Angel Arevalo-Martin, Daniel Garcia-Ovejero, Eduardo Molina-Holgado & Francisco Molina-Holgado. 2017. Cannabinoid Pharmacology. Cannabinoid Pharmacology
135
168
.
John C. Ashton, Megan J. Dowie & Michelle Glass. 2017. The Endocannabinoid System. The Endocannabinoid System
115
186
.
Claire E. Blevins, Kelsey E. Banes, Robert S. Stephens, Denise D. Walker & Roger A. Roffman. (2016) A preliminary evaluation of synthetic cannabinoid use among adolescent cannabis users: Characteristics and treatment outcomes. Addictive Behaviors 63, pages 114-119.
Crossref
Crossref
Loretta T Ford & Jonathan D Berg. (2016) 1-Adamantylamine a simple urine marker for screening for third generation adamantyl-type synthetic cannabinoids by ultra-performance liquid chromatography tandem mass spectrometry. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 53:6, pages 640-646.
Crossref
Crossref
Maren Hermanns-Clausen, Josephine Kithinji, Marco Spehl, Verena Angerer, Florian Franz, Florian Eyer & Volker Auwärter. (2016) Adverse effects after the use of JWH-210 - a case series from the EU Spice II plus project. Drug Testing and Analysis 8:10, pages 1030-1038.
Crossref
Crossref
David M. Wood & Paul I. Dargan. 2016. Current Practice in Forensic Medicine. Current Practice in Forensic Medicine
35
46
.
Seok Heo, Geum Joo Yoo, Ji Yeon Choi, Hyoung Joon Park, Jung-Ah Do, Sooyeul Cho, Sun Young Baek & Sung-Kwan Park. (2016) Simultaneous Analysis of Cannabinoid and Synthetic Cannabinoids in Dietary Supplements Using UPLC with UV and UPLC–MS-MS. Journal of Analytical Toxicology 40:5, pages 350-359.
Crossref
Crossref
Liana Fattore. (2016) Synthetic Cannabinoids—Further Evidence Supporting the Relationship Between Cannabinoids and Psychosis. Biological Psychiatry 79:7, pages 539-548.
Crossref
Crossref
Daniel Castellanos. (2016) Synthetic cannabinoids 2015: An update for pediatricians in clinical practice. World Journal of Clinical Pediatrics 5:1, pages 16.
Crossref
Crossref
Michael F Weaver, John A Hopper & Erik W Gunderson. (2015) Designer drugs 2015: assessment and management. Addiction Science & Clinical Practice 10:1.
Crossref
Crossref
C. Hess, S. Stockhausen, G. Kernbach-Wighton & B. Madea. (2015) Death due to diabetic ketoacidosis: Induction by the consumption of synthetic cannabinoids?. Forensic Science International 257, pages e6-e11.
Crossref
Crossref
Gulser Esen Besli, Mehmet Alper Ikiz, Sema Yildirim & Selcuk Saltik. (2015) Synthetic Cannabinoid Abuse in Adolescents: A Case Series. The Journal of Emergency Medicine 49:5, pages 644-650.
Crossref
Crossref
Allan J. Barnes, Eliani Spinelli, Sheena Young, Thomas M. Martin, Kevin L. Kleete & Marilyn A. Huestis. (2015) Validation of an ELISA Synthetic Cannabinoids Urine Assay. Therapeutic Drug Monitoring 37:5, pages 661-669.
Crossref
Crossref
Kathleen S Bonnici, Paul I Dargan & David M Wood. (2015) Novel psychoactive substances or ‘legal highs'. British Journal of Hospital Medicine 76:9, pages C130-C134.
Crossref
Crossref
C. Lovett, D. M. Wood & P. I. Dargan. (2015) Pharmacology and toxicology of the synthetic cannabinoid receptor agonistsPharmacologie et toxicologie des agonistes synthétiques des récepteurs cannabinoïdes. Réanimation 24:5, pages 527-541.
Crossref
Crossref
Samuel D. Banister, Jordyn Stuart, Trent Conroy, Mitchell Longworth, Madhura Manohar, Corinne Beinat, Shane M. Wilkinson, Richard C. Kevin, David E. Hibbs, Michelle Glass, Mark Connor, Iain S. McGregor & Michael Kassiou. (2015) Structure–activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. Forensic Toxicology 33:2, pages 355-366.
Crossref
Crossref
Michael D. Schwartz, Jordan Trecki, Laura A. Edison, Alaina R. Steck, Justin K. Arnold & Roy R. Gerona. (2015) A Common Source Outbreak of Severe Delirium Associated with Exposure to the Novel Synthetic Cannabinoid ADB-PINACA. The Journal of Emergency Medicine 48:5, pages 573-580.
Crossref
Crossref
Benjamin R. Nordstrom, Sarah C. Akerman & Frances R. Levin. 2015. Psychiatry. Psychiatry
1458
1469
.
Jan van Amsterdam, Tibor Brunt & Wim van den Brink. (2015) The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. Journal of Psychopharmacology 29:3, pages 254-263.
Crossref
Crossref
Brian P. Kersten & Megan E. McLaughlin. (2014) Toxicology and Management of Novel Psychoactive Drugs. Journal of Pharmacy Practice 28:1, pages 50-65.
Crossref
Crossref
Jamie P. Smith, Oliver B. Sutcliffe & Craig E. Banks. (2015) An overview of recent developments in the analytical detection of new psychoactive substances (NPSs). The Analyst 140:15, pages 4932-4948.
Crossref
Crossref
Ritva Karinen, Silja Skogstad Tuv, Elisabeth Leere Øiestad & Vigdis Vindenes. (2015) Concentrations of APINACA, 5F-APINACA, UR-144 and its degradant product in blood samples from six impaired drivers compared to previous reported concentrations of other synthetic cannabinoids. Forensic Science International 246, pages 98-103.
Crossref
Crossref
William D. Wessinger, Jeffery H. Moran & Kathryn A. Seely. 2015. Cannabinoid Modulation of Emotion, Memory, and Motivation. Cannabinoid Modulation of Emotion, Memory, and Motivation
205
224
.
Marisol S. Castaneto, David A. Gorelick, Nathalie A. Desrosiers, Rebecca L. Hartman, Sandrine Pirard & Marilyn A. Huestis. (2014) Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug and Alcohol Dependence 144, pages 12-41.
Crossref
Crossref
Luke Yip & Richard C. Dart. (2014) Is there something more about synthetic cannabinoids?. Forensic Toxicology 32:2, pages 340-341.
Crossref
Crossref
Denise Walker, Clayton Neighbors, Thomas Walton, Adam Pierce, Lyungai Mbilinyi, Debra Kaysen & Roger Roffman. (2014) Spicing up the military: Use and effects of synthetic cannabis in substance abusing army personnel. Addictive Behaviors 39:7, pages 1139-1144.
Crossref
Crossref
Megan E. Musselman & Jeremy P. Hampton. (2014)
“
Not for Human Consumption”: A Review of Emerging Designer Drugs
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34:7, pages 745-757.
Crossref
Crossref
D. M. Wood, S. L. Hill, S. H. L. Thomas & P. I. Dargan. (2014) Using poisons information service data to assess the acute harms associated with novel psychoactive substances. Drug Testing and Analysis 6:7-8, pages 850-860.
Crossref
Crossref
Sherrel G. Howard. 2014. Drugs of Abuse. Drugs of Abuse
153
165
.
Tracy L. Brewer & Margie Collins. (2014) A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. Journal for Specialists in Pediatric Nursing 19:2, pages 119-126.
Crossref
Crossref
Jolanta B. Zawilska & Jakub Wojcieszak. (2013) Spice/K2 drugs ? more than innocent substitutes for marijuana. The International Journal of Neuropsychopharmacology 17:03, pages 509-525.
Crossref
Crossref
Joan A. Culpepper-Morgan. (2014) SPICE/K2 Synthetic Marijuana-Induced Toxic Hepatitis Treated with N-Acetylcysteine. American Journal of Case Reports 15, pages 584-588.
Crossref
Crossref
Rossella Gottardo, Daniela Sorio, Giacomo Musile, Elisa Trapani, Catia Seri, Giovanni Serpelloni & Franco Tagliaro. (2013) Screening for synthetic cannabinoids in hair by using LC-QTOF MS: A new and powerful approach to study the penetration of these new psychoactive substances in the population. Medicine, Science and the Law 54:1, pages 22-27.
Crossref
Crossref
Joel Schlatter. 2014.
291
311
.
Frank Musshoff, Burkhard Madea, Gerhard Kernbach-Wighton, Wolfgang Bicker, Stefan Kneisel, Melanie Hutter & Volker Auwärter. (2013) Driving under the influence of synthetic cannabinoids (“Spice”): a case series. International Journal of Legal Medicine 128:1, pages 59-64.
Crossref
Crossref
Jihyun Kim, Sanghwan In, Yuran Park, Meejung Park, Eunmi Kim & Sooyeun Lee. (2013) Deposition of JWH-018, JWH-073 and their metabolites in hair and effect of hair pigmentation. Analytical and Bioanalytical Chemistry 405:30, pages 9769-9778.
Crossref
Crossref
R. Kronstrand, M. Roman, M. Andersson & A. Eklund. (2013) Toxicological Findings of Synthetic Cannabinoids in Recreational Users. Journal of Analytical Toxicology 37:8, pages 534-541.
Crossref
Crossref
Amy L. Patton, Kathryn A. Seely, Krishna C. Chimalakonda, Johnny P. Tran, Matthew Trass, Art Miranda, William E. Fantegrossi, Paul D. Kennedy, Paul Dobrowolski, Anna Radominska-Pandya, Keith R. McCain, Laura P. James, Gregory W. Endres & Jeffery H. Moran. (2013) Targeted Metabolomic Approach for Assessing Human Synthetic Cannabinoid Exposure and Pharmacology. Analytical Chemistry 85:19, pages 9390-9399.
Crossref
Crossref
Fermin BarruetoJr.Jr., Rajender Gattu & Maryann Mazer-Amirshahi. (2013) Updates in the General Approach to the Pediatric Poisoned Patient. Pediatric Clinics of North America 60:5, pages 1203-1220.
Crossref
Crossref
Christopher Y. Hopkins & Brandi L. Gilchrist. (2013) A Case of Cannabinoid Hyperemesis Syndrome Caused by Synthetic Cannabinoids. The Journal of Emergency Medicine 45:4, pages 544-546.
Crossref
Crossref
L. K. Brents, S. M. Zimmerman, A. R. Saffell, P. L. Prather & W. E. Fantegrossi. (2013) Differential Drug-Drug Interactions of the Synthetic Cannabinoids JWH-018 and JWH-073: Implications for Drug Abuse Liability and Pain Therapy. Journal of Pharmacology and Experimental Therapeutics 346:3, pages 350-361.
Crossref
Crossref
Maren Hermanns-Clausen, Stefan Kneisel, Melanie Hutter, Bela Szabo & Volker Auwärter. (2013) Acute intoxication by synthetic cannabinoids - Four case reports. Drug Testing and Analysis 5:9-10, pages 790-794.
Crossref
Crossref
Max Spaderna, Peter H. Addy & Deepak Cyril D’Souza. (2013) Spicing things up: synthetic cannabinoids. Psychopharmacology 228:4, pages 525-540.
Crossref
Crossref
Samuel D. Banister, Shane M. Wilkinson, Mitchell Longworth, Jordyn Stuart, Nadine Apetz, Katrina English, Lance Brooker, Catrin Goebel, David E. Hibbs, Michelle Glass, Mark Connor, Iain S. McGregor & Michael Kassiou. (2013) The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse. ACS Chemical Neuroscience 4:7, pages 1081-1092.
Crossref
Crossref
Duccio Papanti, Fabrizio Schifano, Giulia Botteon, Francesca Bertossi, Jason Mannix, Daniela Vidoni, Matteo Impagnatiello, Elisabetta Pascolo‐Fabrici & Tommaso Bonavigo. (2013) “Spiceophrenia”: a systematic overview of “Spice”‐related psychopathological issues and a case report. Human Psychopharmacology: Clinical and Experimental 28:4, pages 379-389.
Crossref
Crossref
A. Arntson, B. Ofsa, D. Lancaster, J. R. Simon, M. McMullin & B. Logan. (2013) Validation of a Novel Immunoassay for the Detection of Synthetic Cannabinoids and Metabolites in Urine Specimens. Journal of Analytical Toxicology 37:5, pages 284-290.
Crossref
Crossref
Lucas A. Johnson, Rebecca L. Johnson & Ray-Bernard Portier. (2013) Current “Legal Highs”. The Journal of Emergency Medicine 44:6, pages 1108-1115.
Crossref
Crossref
Maren Hermanns‐Clausen, Stefan Kneisel, Bela Szabo & Volker Auwärter. (2012) Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108:3, pages 534-544.
Crossref
Crossref
David McQuade, Simon Hudson, Paul I. Dargan & David M. Wood. (2012) First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. European Journal of Clinical Pharmacology 69:3, pages 373-376.
Crossref
Crossref
Savithiri Ratnapalan. (2013) Legal substances and their abuse: Legal highs. Journal of Paramedic Practice 5:1, pages 40-51.
Crossref
Crossref
Volker Auwärter, Paul I. Dargan & David M. Wood. 2013. Novel Psychoactive Substances. Novel Psychoactive Substances
317
343
.
Laura M. TormoehlenNeeraj Kumar. (2012) Neurotoxicology. Neurology Clinical Practice 2:4, pages 301-310.
Crossref
Crossref
Felecia N. JinwalaMayank Gupta. (2012) Synthetic Cannabis and Respiratory Depression. Journal of Child and Adolescent Psychopharmacology 22:6, pages 459-462.
Crossref
Crossref
Kathryn A. Seely, Jeff Lapoint, Jeffery H. Moran & Liana Fattore. (2012) Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Progress in Neuro-Psychopharmacology and Biological Psychiatry 39:2, pages 234-243.
Crossref
Crossref
Gustavo Merola, Zeineb Aturki, Giovanni D’Orazio, Rossella Gottardo, Teodora Macchia, Franco Tagliaro & Salvatore Fanali. (2012) Analysis of synthetic cannabinoids in herbal blends by means of nano-liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis 71, pages 45-53.
Crossref
Crossref
Jason M. Wiebelhaus, Justin L. Poklis, Alphonse Poklis, Robert E. Vann, Aron H. Lichtman & Laura E. Wise. (2012) Inhalation exposure to smoke from synthetic ?marijuana? produces potent cannabimimetic effects in mice. Drug and Alcohol Dependence 126:3, pages 316-323.
Crossref
Crossref
Rossella Gottardo, Anna Bertaso, Jennifer Pascali, Daniela Sorio, Giacomo Musile, Elisa Trapani, Catia Seri, Giovanni Serpelloni & Franco Tagliaro. (2012) Micellar electrokinetic chromatography: A new simple tool for the analysis of synthetic cannabinoids in herbal blends and for the rapid estimation of their logP values. Journal of Chromatography A 1267, pages 198-205.
Crossref
Crossref
Krishna C. Chimalakonda, Kathryn A. Seely, Stacie M. Bratton, Lisa K. Brents, Cindy L. Moran, Gregory W. Endres, Laura P. James, Paul F. Hollenberg, Paul L. Prather, Anna Radominska-Pandya & Jeffery H. Moran. (2012) Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands. Drug Metabolism and Disposition 40:11, pages 2174-2184.
Crossref
Crossref
Justin L. Poklis, Dorra Amira, Laura E. Wise, Jason M. Wiebelhaus, Brenda J. Haggerty, Aron H. Lichtman & Alphonse Poklis. (2012) Determination of naphthalen‐1‐yl‐(1‐pentylindol‐3‐yl)methanone (JWH‐018) in mouse blood and tissue after inhalation exposure to ‘buzz’ smoke by HPLC/MS/MS. Biomedical Chromatography 26:11, pages 1393-1398.
Crossref
Crossref
Jiří Patočka & Kamil Kuča. (2012) New synthetic cannabinoids are coming to the drug scene. Kontakt 14:3, pages 369-377.
Crossref
Crossref
L. Hruba, B. C. Ginsburg & L. R. McMahon. (2012) Apparent Inverse Relationship between Cannabinoid Agonist Efficacy and Tolerance/Cross-Tolerance Produced by 9-Tetrahydrocannabinol Treatment in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics 342:3, pages 843-849.
Crossref
Crossref
Babak Tofighi & Joshua D. Lee. (2012) Internet Highs—Seizures After Consumption of Synthetic Cannabinoids Purchased Online. Journal of Addiction Medicine 6:3, pages 240-241.
Crossref
Crossref
David M. Wood & Paul I. Dargan. (2012) Novel Psychoactive Substances. Therapeutic Drug Monitoring 34:4, pages 363-367.
Crossref
Crossref
Megan Grabenauer, Wojciech L. Krol, Jenny L. Wiley & Brian F. Thomas. (2012) Analysis of Synthetic Cannabinoids Using High-Resolution Mass Spectrometry and Mass Defect Filtering: Implications for Nontargeted Screening of Designer Drugs. Analytical Chemistry 84:13, pages 5574-5581.
Crossref
Crossref
Sadip Pant, Bhagirath Dholaria, Varinder Kaur, Samayuktha Ramavaram, Mary Ukor, Abhishek Deshmukh & Gerson A. Teran. (2012) Spicy Seizure. The American Journal of the Medical Sciences 344:1, pages 67-68.
Crossref
Crossref
K. G. Shanks, T. Dahn, G. Behonick & A. Terrell. (2012) Analysis of First and Second Generation Legal Highs for Synthetic Cannabinoids and Synthetic Stimulants by Ultra-Performance Liquid Chromatography and Time of Flight Mass Spectrometry. Journal of Analytical Toxicology 36:6, pages 360-371.
Crossref
Crossref
K. G. Shanks, T. Dahn & A. R. Terrell. (2012) Detection of JWH-018 and JWH-073 by UPLC-MS-MS in Postmortem Whole Blood Casework. Journal of Analytical Toxicology 36:3, pages 145-152.
Crossref
Crossref
Lisa K. Brents, Anna Gallus-Zawada, Anna Radominska-Pandya, Tamara Vasiljevik, Thomas E. Prisinzano, William E. Fantegrossi, Jeffery H. Moran & Paul L. Prather. (2012) Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochemical Pharmacology 83:7, pages 952-961.
Crossref
Crossref
Donald G. Barceloux. 2012. Medical Toxicology of Drug Abuse. Medical Toxicology of Drug Abuse
886
931
.
Vlasios Brakoulias. (2012) Products containing synthetic cannabinoids and psychosis. Australian & New Zealand Journal of Psychiatry 46:3, pages 281-282.
Crossref
Crossref
Christopher D. Rosenbaum, Stephanie P. Carreiro & Kavita M. Babu. (2012) Here Today, Gone Tomorrow…and Back Again? A Review of Herbal Marijuana Alternatives (K2, Spice), Synthetic Cathinones (Bath Salts), Kratom, Salvia divinorum, Methoxetamine, and Piperazines. Journal of Medical Toxicology 8:1, pages 15-32.
Crossref
Crossref
Aaron B. Schneir & Todd Baumbacher. (2011) Convulsions Associated with the Use of a Synthetic Cannabinoid Product. Journal of Medical Toxicology 8:1, pages 62-64.
Crossref
Crossref
Silja Skogstad Tuv, Maren Cecilie Strand, Ritva Karinen, Elisabeth Leere Øiestad, Asbjørg S. Christophersen & Vigdis Vindenes. (2012) Syntetiske cannabinoider - effekt og forekomst. Tidsskrift for Den norske legeforening 132:20, pages 2285-2288.
Crossref
Crossref
B. C. Ginsburg, D. R. Schulze, L. Hruba & L. R. McMahon. (2011) JWH-018 and JWH-073: 9-Tetrahydrocannabinol-Like Discriminative Stimulus Effects in Monkeys. Journal of Pharmacology and Experimental Therapeutics 340:1, pages 37-45.
Crossref
Crossref
M. Perrin, Y. Lecompte, O. Roussel, R. Le Boisselier, J. Bourgine & A. Coquerel. 2012. Traité De Toxicologie Médico-judiciaire. Traité De Toxicologie Médico-judiciaire
507
547
.
Rossella Gottardo, Anna Chiarini, Ilaria Dal Prà, Catia Seri, Claudia Rimondo, Giovanni Serpelloni, Ubaldo Armato & Franco Tagliaro. (2012) Direct screening of herbal blends for new synthetic cannabinoids by MALDI‐TOF MS. Journal of Mass Spectrometry 47:1, pages 141-146.
Crossref
Crossref